Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C

Journal of Clinical Virology

Volumn 52, Issue 2, 2011, Pages 133-137

  Vermehren, Johannes ^a   Yu, Ming Lung ^b   Monto, Alexander ^c   Yao, Joseph D ^d   Anderson, Christopher ^e   Bertuzis, Rasa ^e   Schneider, George ^e   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e Abbott Molecular Inc   (United States)

Author keywords

BDNA; Chronic hepatitis C; Early virologic response; Pegylated interferon; Rapid virologic response; RealTime HCV; Response guided therapy; Ribavirin; TMA

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT DURATION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG MONITORING; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 80052714532     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.07.007     Document Type: Article

References (31)

1. World Health Organization Viral hepatitis: report by the secretariat 2009, http://appswhoint/gb/ebwha/pdf_files/EB126/B126_15-en.pdf [accessed 10.02.11.].
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
3. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
4. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374.
5. McCaughan G.W., Omata M., Amarapurkar D., Bowden S., Chow W.C., Chutaputti A., et al. Asian Pacific Association for the study of the liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007, 22(5):615-633.
6. Sarrazin C., Berg T., Ross R.S., Schirmacher P., Wedemeyer H., Neumann U., et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010, 48(2):289-351.
7. Craxi A. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55(2):245-264.
8. de Segadas-Soares J.A., Villela-Nogueira C.A., Perez R.M., Nabuco L.C., Brandao-Mello C.E., Coelho H.S. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis C patients treated with peginterferon-alpha2b and ribavirin?. J Clin Gastroenterol 2009, 43(4):362-366.
9. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40kd)/ribavirin therapy. Hepatology 2006, 43(5):954-960.
10. Mangia A., Minerva N., Bacca D., Cozzolongo R., Ricci G.L., Carretta V., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47(1):43-50.
11. Fried M.W., Hadziyannis S.J., Shiffman M.L., Messinger D., Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011, 55(1):69-75.
12. von Wagner M., Huber M., Berg T., Hinrichsen H., Rasenack J., Heintges T., et al. Peginterferon-alpha-2a (40kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129(2):522-527.
13. Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Sola R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357(2):124-134.
14. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49(4):634-651.
15. Poordad F.F. Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther 2010, 31(12):1251-1267.
16. de Leuw P., Sarrazin C., Zeuzem S. How to use virological tools for the optimal management of chronic hepatitis C. Liver Int 2011, 31(1):3-12.
17. Bossler A., Gunsolly C., Pyne M.T., Rendo A., Rachel J., Mills R., et al. Performance of the COBAS((R)) AmpliPrep/COBAS TaqMan((R)) automated system for hepatitis C virus (HCV) quantification in a multi-center comparison. J Clin Virol 2011, 50(2):100-103.
18. Sarrazin C., Gartner B.C., Sizmann D., Babiel R., Mihm U., Hofmann W.P., et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 2006, 44(3):729-737.
19. Sizmann D., Boeck C., Boelter J., Fischer D., Miethke M., Nicolaus S., et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007, 38(4):326-333.
20. Vermehren J., Kau A., Gartner B.C., Gobel R., Zeuzem S., Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008, 46(12):3880-3891.
21. Pyne M.T., Konnick E.Q., Phansalkar A., Hillyard D.R. Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay. J Clin Microbiol 2009, 47(9):2872-2878.
22. Halfon P., Bourliere M., Penaranda G., Khiri H., Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol 2006, 44(7):2507-2511.
23. Michelin B.D., Muller Z., Stelzl E., Marth E., Kessler H.H. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol 2007, 38(2):96-100.
24. Schutten M., Fries E., Burghoorn-Maas C., Niesters H.G. Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA. J Clin Virol 2007, 40(2):99-104.
25. Tuaillon E., Mondain A.M., Ottomani L., Roudiere L., Perney P., Picot M.C., et al. Impact of hepatitis C virus (HCV) genotypes on quantification of HCV RNA in serum by COBAS AmpliPrep/COBAS TaqMan HCV test, Abbott HCV realtime assay [corrected] and VERSANT HCV RNA assay. J Clin Microbiol 2007, 45(9):3077-3081.
26. Chevaliez S., Bouvier-Alias M., Pawlotsky J.M. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol 2009, 47(6):1726-1732.
27. Okamoto H., Tokita H., Sakamoto M., Horikita M., Kojima M., Iizuka H., et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993, 74(11):2385-2390.
28. Sarrazin C., Dragan A., Gartner B.C., Forman M.S., Traver S., Zeuzem S., et al. Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. J Clin Virol 2008, 43(2):162-168.
29. Martinot-Peignoux M., Khiri H., Leclere L., Maylin S., Marcellin P., Halfon P. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. J Clin Virol 2009, 46(3):216-221.
30. Sarrazin C., Shiffman M.L., Hadziyannis S.J., Lin A., Colucci G., Ishida H., et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 2010, 52(6):832-838.
31. Bortoletto G., Campagnolo D., Mirandola S., Comastri G., Severini L., Pulvirenti F.R., et al. Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy. J Clin Virol 2011, 50(3):217-220.